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TBlunt Thoracic Aortic Injuries: An Autopsy Study
Teixeira PG, Inaba K, Barmparas G, et. al. J Trauma 2011;70:197-202.
Conclusion: One third of patients with fatal blunt trauma have tho-
racic aortic injuries. The majority of deaths occur at the scene of the injury.
Summary: There have been recent paradigm shifts in the management
of blunt thoracic aortic trauma, including more widespread imaging using
CT scanning, aggressive blood pressure control of patients who reach the
hospital alive, delayed treatment of thoracic aortic injuries and more fre-
quent use of endovascular techniques for repair of blunt thoracic trauma.
These changes appear to have resulted in a decline in mortality from 22% to
13% for patients with thoracic aortic injuries who reach the hospital alive
(Demetriades D. J Trauma 2008;64:1415-8). Many patients with blunt
thoracic injury, however, cannot benefit from these advnces because they die
at the scene of the accident. To develop some sense of the magnitude of this
problem the authors analyzed autopsy findings in a series of blunt traumatic
fatalities. They reviewed autopsies for blunt trauma performed by the Los
Angeles County Coroner’s Office in 2005. Victims without thoracic aortic
trauma were compared with those with a traumatic thoracic aortic injury
with respect to patterns of associated injuries and differences in baseline
characteristics. During the study time there were 881 fatal victims of blunt
trauma received by the Los Angeles County Department of Coroner. Of
these 304 (35%) underwent a full autopsy and were included in the analysis
here. Average age was 43 21 years and 71% were men. The most common
mechanism of injury was a motor vehicle accident (50%) and the second
most common was a pedestrians struck by an auto (37%). 102 of the 304
victims (34%) had a thoracic aortic injury. The descending thoracic aorta was
the site of injury in 66%. Compared to patients without thoracic aortic
injuries those with thoracic aortic injuries were more likely to have a cardiac
injury (44% versus 25%; P .001), hemothorax (86% versus 56%; P .001),
rib fractures (86% versus 72%; P  .006), and intra-abdominal injury (74%
versus 49%; P  .001). Death at the scene was more likely if you had a
thoracic aortic injury (80% versus 63%; P  .002).
Comment: It is not surprising most patients with thoracic aortic injury
die at the accident scene.Motor vehicle accidents serve as the greatest source
of thoracic aortic injury. It is interesting that despite advances in automotive
and safety engineering the prevalence of blunt thoracic aortic injury inmotor
vehicle accidents does not seem to have been impacted by engineering
advances. The association of thoracic aortic injury with motor vehicle
accidents appears very similar to that, identified by Parmley, et. al. fifty years
ago (Parmley LF. Circulation 1958;17:1086-101). However, it is possible
engineering advances may have reduced the fatality rate of blunt aortic
thoracic trauma following motor vehicle trauma without affecting its prev-
alence.
Clopidogrel Versus Dipyridamole in Addition to Aspirin in Reducing
Embolization Detected with Ambulatory Transcranial Doppler: A
Randomized Trial
King A, Bath PM, Markus HS. Stroke 2011;42:650-5.
Conclusions: Dipyridamole and clopidogrel reduce cerebral emboli-
zation to a similar extent. Combinations of aspirin plus dipyridamole and
aspirin plus clopidogrel and are likely to have similar efficacies in the early
secondary prevention of stroke.
Summary: Patients with transient ischemia attack and stroke secondary
to large artery stenosis are at high risk for early recurrent stoke (Rothwell
PM, et al. Lancet Neurol 2006;5:323-31). Most data assessing the effects of
antiplatelet agents to prevent recurrent stroke are long term secondary
prevention trials and the combination of aspirin and Dipyridamole is more
effective than aspirin but equivalent to clopidogrel alone. (Sacco RL, et al.
N Engl J Med 2008;359:1238-51). The authors postulate best antiplatelet
therapy for early secondary stroke prevention may differ from that for long
term secondary prevention.Higher risks of bleedingmay be acceptable given
the high risk of early recurrent stoke following the initial event. Detection of
embolic signals, by ambulatory transcranial Doppler (TCD) was used as a
surrogate endpoint for clinical neurological events in the prediction of future
stoke with symptomatic carotid stenosis (Markus HS, et al. Circulation
2005;111:2233-40). This trial, termed The Ambulatory Dual Antiplatelet
(AMBDAP) study, was designed to determine whether dual antiplatelet
therapy with aspirin and clopidogrel was more effective than therapy with
aspirin and dipyridamole in preventing detection of embolic signals in
patients with acute symptomatic carotid stenosis. This study was based on a
new technique of ambulatory transcranial Doppler monitoring felt to be
more sensitive to embolic signals in patients with carotid stenosis (Mackin-
non AD, et al. Stroke 2005;36:1726-30).
c
4Patients with recent symptomatic carotid stenosis were recruited. Am-
ulatory transcranial Doppler and platelet aggregometry were performed at
aseline and at 48 hours. All patients were on aspirin, and were then
andomized to either receive dipyridamole or clopidogrel. TCD recordings
ere analyzed off line with interpreters masked to subject identity. There
ere 60 patients recruited to the study with 30 in each arm. There was no
ifference of the primary endpoint of change in embolic signal frequency
etween groups (P .36). In patients who had detectable embolic signals at
aseline there was no difference in reduction of embolic signal frequency
dipradamole (75.5; SD 17.7%) versus clopidogrel (77.5; SD 20.5%; P 
77)]. Platelet aggregation was not different between regimens at baseline.
t 48 hours, adenosine 5-diphosphate aggregation rate (but not collagen)
as lower with clopidogrel (P  .001).
Comment: In patients with acute extracranial cerebral vascular disease
oth clopidogrel and dipyridamole when added to aspirin therapy will
educe embolization rates detected by transcranial Doppler. The data has
mplications for design of future efficacy trials in that embolic signals
etected by TCD have been shown to a strong independent predictor of
troke rates in patients with extracranial symptomatic cerebral vascular
isease (King A et al. Stroke 2009;40:3711-7). The platelet aggregation
tudies confirmed the different mechanisms of action of clopidogrel and
ipyridamole in reducing platelet aggregation. Nevertheless the clinical end
oints with these two medications when added to aspirin would, based on
his data, be predicated to be the same with respect to secondary prevention
f acute symptomatic extracranial carotid artery disease. Phase III trials will
e needed to confirm clinical efficacy.
oes Carotid Intima-Media Thickness Regression Predict Reduction
f Cardiovascular Events? A Meta-Analysis of 41 Randomized Trials
ostanzo P, Perrone-Filardi P, Vassallo E. et al. J Am Coll Cardiol 2010;
6:2006-20.
Conclusion: Slowed progression or regression of carotid intima-media
hickness (IMT) induced by drug therapy does not translate into reduction
n clinical cardiovascular events.
Summary: Carotid intima-media thickness (IMT) predicts cardiovas-
ular events. IMT is therefore a potentially attractive biomarker as a thera-
eutic target in subjects at increased cardiovascular risk. IMT is considered a
anifestation of subclinical atherosclerosis. It has been included in the list of
rgan damaged conditions in European Hypertensive Guidelines and in the
uropean Prevention Guidelines. (Mancia G, et al. Eur Heart J 2007;28:
462-536, and Graham I, et al. Eur J Cardiovasc Prev Rehabil 2007;14
uppl 2:e1-40). IMT changes have been employed as surrogate clinical
nd-points in randomized clinical studies of lipid lowering agents, antihy-
ertensive agents, oral antidiabetic agents, and antioxidant drugs in subjects
t intermediate to high cardiovascular risk. Information verifying whether
hanges in IMT were associated with consistent changes in cardiovascular
isk profile would be relevant for interpretation of IMT variations and
urrogate clinical-end points and for identifying therapeutic targets for
ardiovascular therapies.
The author’s designed this meta-analysis to verify whether IMT regres-
ion is associated with reduced incidence of cardiovascular events. Cochrane
nd the Medline databases were searched for articles published until August
009. Included articles were randomized trials that assessed carotid IMT at
aseline and at follow-up and that also reported clinical end-points. A
eighted random-affects analysis was used to determine a relationship
etween mean and maximum IMT changes and outcome. Baseline patient
haracters, cardiovascular risk profile, IMT at baseline and follow up and
uality of the trials were also explored. Estimates and effects were calculated
ith a fixed-effects model, random-effects model or Peto method. There
ere 18,307 participants and 41 trials included in the analysis. There were
ignificant reductions in coronary heart disease, cerebral vascular disease
vents and all cause death induced by active treatments in the trial. However,
here was no significant relationship between IMT regression and coronary
eart disease events (tau, 0.91; P  .37), cerebral vascular events (tau,
0.32; P .75) and all cause death (tau,0.41; P .69). The association
etween IMT changes and clinical outcomes was not influenced by subject’s
aseline characters, cardiovascular risk profile, IMT at baseline, follow up or
uality of the trials.
Comment: The principle finding of the study is carotid IMT changes
o not correlate with changes inmajor cardiovascular events that are induced
y drug treatments in subjects at intermediate to high cardio vascular risk.
he US Preventative Task Force considers correlation of IMT changes with
linical events to be unproven (HelfandM, et al. Ann InternMed 2009;151:
96-507). There may be many unknown determinates of IMT that reduce
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August 2011582 Abstractsthe clinical strength and statistical significance of IMT changes associated
with cardiovascular outcomes when compared tomore direct atherosclerotic
risk factors. It may also be, that atherosclerosis in the carotid artery, is not
generally representative of atherosclerosis throughout the body. Atheroscle-
rotic plaques in the carotid artery grow longitudinally at twice the rate that
they grow in thickness. Therefore, IMT may be a less sensitive measure of
plaque evolution than total plaque burden (Mackinnon AD, et al. Stroke
2004;35:2150-4). The bottom line, however, is that while IMT increase
indicates increased cardiovascular risk, changes in IMT induced by drug
therapy do not appear to reflect clinical outcome.
Outcomes of Endovascular Repair of Ruptured Descending Thoracic
Aortic Aneurysms
Jonker FH, Verhagen HJ, Lin PH, et al. Circulation 2010;121:2718-23.
Conclusions: Endovascular repair of ruptured descending thoracic
aortic aneurysms (TAAs) provides encouraging results but is associated with
a significant rate of neurologic complications and a relatively high rate of
endoleak.
Summary: Ruptured TAAs are relatively rare with reported an inci-
dence of only about 5 per 100,000. Mortality is high and is thought to
exceed 90% (Johannson G. J Vasc Surg 1995;21:985-8). There is little
information on endovascular treatment of ruptured TAAs. Ruptures of true
degenerative TAAs are often lumped in other series combining penetrating
aortic ulcers, thoracic aortic trauma and complications of type B dissection.
The authors accumulated a “pure” series of ruptured descending TAAs by
identifying patients treated with endovascular repair for ruptured AA at 7
different centers between July 2002 and July 2009. There were 87 patients
in this retrospective study with a mean age of 69.8  12 years and 69.0%
were men. At presentation 40.2% were hemodynamically unstable and
21.8% were in hypovolemic shock. Following endovascular repair mortality
was 18.4%. Increased 30-day mortality after adjusting for age, was associated
with hypovolemic shock (OR, 4.75; 95% CI, 1.37 to 16.5; P  .014) and
hemothorax on admission (OR, 6.65; 95% CI, 1.64 to 27.1; P  .008).
Ruptured TAA s were successfully excluded during TEVAR in 95.4%. Stroke
occurred in 8% (n  7). Four patients died of stroke. Post operative
paraplegia occurred in 8% (n  7) and was permanent in 2 patients and
transient in 5. There was an 18.4% incidence of endoleak during the first 30
days (n  16) with type 1 of endoleaks occurring in 10 patients, type 2
endoleaks in 5 patients and a type 3 endoleak in one patient. There were 2
late aortic esophageal fistulas that were fatal. Estimated freedom from
aneurysm related death or intervention was 54.9% at 4 years.
Comment: Short term mortality rates of TEVAR treatment of de-
scending TAA rupture compares favorably with open repair of descending
TAA rupture (Schermerhorn ML, et al. J Vasc Surg 2008;48:821-7).
Endovascular repair of a descending ruptured TAA does appear to be
associated with a high rate of neurologic and procedurally related complica-
tions, particularly type 1 endoleak. The data make it reasonably to consider
TEVAR for repair of a ruptured descending TAA but morbidity and mor-
tality are still significant.
Risk of Early Carotid Endarterectomy for Symptomatic Carotid
Stenosis
Brinjikji W, Rabinstein AA, Meyer FB, et al. Stroke 2010;41:2186-90.
Conclusion: Carotid endarterectomy (CEA) can be performed with
slightly increased, but acceptable, risk in symptomatic patients within two
weeks of stroke or transient ischemic attack.
Summary:Current guidelines from the American Academy of Neurol-
ogy and the American Heart Association indicate patients with symptomatic
carotid stenosis should preferentially undergo CEA within 2 weeks of the
symptomatic event (Chaturvedi S, et al. Neurology 2005;65:794-801, and
Sacco RL, et al. Stroke 2006;37:577-617). However many patients are not
operated within 2 weeks. In addition, traditional “surgical wisdom” has
shied away from acute operation especially in stroke patients for fear of a
higher incidence of complications (Naylor AR. Surgeon 2007;5:23-30).
The authors examined their institutional experience with CEA with
particular analysis of symptomatic patients operated within 2 weeks of
symptoms. Symptomatic patients were not considered for early CEA if they
had an infarct involving more than one third of the middle cerebral artery
territory or if a patient had a fixed disabling deficit or an unstable medical
condition. When those conditions were not present patients were operated
soon after evaluation irrespective of the interval from the symptomatic event.
The authors felt delays were usually related to delayed referral after symptom
onset.
The patients analyzed were those operated between January 2004 and
May 2009. Patients were divided into three groups. Group 1 were asymp-
tomatic, group 2 were symptomatic patients operated 2 weeks after their
symptom, and group 3 were symptomatic patients operated on 2 weeks
after their symptom (transient ischemic attack or stroke). Primary outcome
was any myocardial infarction, stroke, or death within 30 days of the
c
operation. A secondary endpoint was transient ischemic attack within 30
ays postoperatively.
There were 532 carotid endarterectomies performed in 507 patients.
here were 500 patients with 525 CEA’s who had 30 day follow up. There
ere 278 in group 1, 105 in group 2, and 142 in group 3. The primary
utcome occurred in 5 patients in group 1 (1.8%); 1 patient in group 2
1.0%); and 6 patients in group 3 (4.2%). There were no significant differ-
nces in the rate of primary outcome among the three groups (P  .17).
here was also no significant difference comparing group 2 to group 3 (P
24).
Comment: This study has all the limitations of a single institution
etrospective review. The biggest problem is insuring patients in group 2 and
roup 3 did in fact only differ primarily by referral pattern and not by other
ore pertinentmedical conditions. The percentage of patients with stroke in
roup 2 and group 3 was similar (36.2% versus 35.2%), but we really don’t
now whether the severity of the strokes were the same and whether
erioperative management and other co-morbidities were the same. Never-
heless, this study lends further support to a policy of performance of CEA in
elected patients shortly after the onset of a neurologic symptom.
uperior Nationwide Outcomes of Endovascular versus Open Repair
or Isolated Descending Thoracic Aortic Aneurysm in 11,669 Patients
opaldas RR, Huh J, Dao TK, et. al. J Thorac Cardiovas Surg 2010;140:
001-10.
Conclusion: Compared with open aortic repair (OAR) thoracic endo-
ascular aneurysm repair (TEVAR) is associated with shorter hospital stay,
imilar mortalities, fewer complications, and increased hospital charges.
Summary: The first endovascular prosthesis was approved in 2005 for
horacic endovascular aneurysm repair in the United States. The technology
as been widely adopted but there is little information available on TEVAR
ationwide outcomes for treatment of descending isolated thoracic aortic
neurysm (TAA). The authors therefore compared in hospital outcomes of
EVAR and open descending TAA repairs performed in the United States
uring the initial 3 years following approval of the GORETAG device. They
sed nationwide data to identify patients who had undergone surgery for
solated descending TAA from 2006-2007. Patients treated for aortic dis-
ection or rupture or who underwent simultaneous treatment of other aortic
egments were excluded. There were 11,669 patients analyzed and 9,106
ad conventional open aneurysm repair (OAR) and 2,563 had TEVAR.
atients were compared for mortality and hospital stay as well as discharge
tatus, morbidity, and hospital charges.
Patients undergoing TEVAR were older (69.5  12.7 versus 60.2 
4.2 years; P .001) and had higher preoperative morbidity. Length of stay
as shorter for TEVAR patients (7.7  11 versus 8.8  7.9 days). Unad-
usted mortality was similar for TEVAR (2.3%) and OAR (2.2%; P  1.0).
here were similar proportions of non elective interventions in the two
roups (TEVAR 15.9% versus OAR 15.8%; P .9). Risk adjusted mortality
ates with TEVAR and OAR were similar. TEVAR patients, however, had
0% fewer complications (OR, 0.39; P  .001). TEVAR patients were 4
imes more likely to have a routine discharge home than OAR patients.
EVAR hospital charges were greater by $6713 (95% CI, 1869- 11,556;
 .001).
Comment: Surgical procedures with good outcomes and that are
easy” to perform are adopted widely. More difficult procedures are gener-
lly restricted to high volume centers. Wide spread adoption of TEVAR is
ppropriate. Even though TEVAR was selectively performed in patients
lmost a decade older than the OAR patients, outcomes were comparable, if
ot superior, for TEVAR versus OAR with TEVAR having significantly
etter risk adjusted morbidity, primarily from lower incidences of neuro-
ogic, respiratory and pulmonary complications. Additional data is needed to
etermine whether TEVAR has volume dependent outcomes, or like endo-
ascular abdominal aortic aneurysm repair, can be performed with relatively
ow morbidity in low volume hospitals. Such data is needed to determine
hether thoracic aortic aneurysm patients should be treated in centers
edicated to treatment of aortic disease or if TEVAR will permit more wide
pread treatment of thoracic aortic pathology in community and smaller
egional hospitals.
iming of Preoperative Beta-Blocker Treatment in Vascular Surgery
atients Influence on Postoperative Outcome
lu WJ, van Kujik JP, Chonchol M, et.al. J Am Coll Cardiol 2010;56:
922-9.
Conclusion: -blocker treatment initiated more than one week before
ascular surgery is associated with lower preoperative heart rate and im-
roved cardiovascular outcomes compared to treatment initiated less than
ne week preoperatively.
Summary:Most randomized control trials and observational studies of
-blocker therapy in vascular surgical patients indicate a favorable effect on
ardiovascular outcome with perioperative -blockers. Benefit may be sec-
ndary to heart rate control, reduction of systolic pressure, reduction in
